Latest Medical Therapies for Cutaneous Squamous Cell Carcinoma

Squamous cell carcinoma (SCC) is a type of skin cancer that affects the cells in the outer layer of the skin. It is one of the most common types of skin cancer and is typically caused by prolonged sun exposure.

With the latest advancements in medical research, there are new medications and treatment options available for SCC that are being evaluated in clinical trials. These medications have the potential to improve the effectiveness of treatment while minimizing side effects.

One of the most promising new medications for SCC is the immunotherapy drug, pembrolizumab. Pembrolizumab is a monoclonal antibody that targets the PD-1 protein, which is found on the surface of certain cancer cells. By blocking the PD-1 protein, pembrolizumab allows the immune system to attack and destroy the cancer cells. In clinical trials, pembrolizumab has shown to be effective in treating advanced SCC, and has been granted accelerated approval by the FDA for this indication.

Another new medication for SCC is the oral tyrosine kinase inhibitor, Lenvatinib. Lenvatinib is an oral medication that targets the VEGFR2 protein which is found on the surface of cancer cells. By blocking the VEGFR2 protein, Lenvatinib is able to inhibit the growth and spread of cancer cells. In clinical trials, Lenvatinib has shown to be effective in treating advanced SCC and has been granted FDA approval for this indication.

Lastly, the combination of Durvalumab and Tremelimumab is also being evaluated in clinical trials for the treatment of SCC. Durvalumab is an immunotherapy drug that targets the PD-L1 protein and Tremelimumab is a CTLA-4 inhibitor, that when combined together, enhance the immune system’s ability to attack cancer cells. These clinical trials are ongoing, but the results so far have been promising and the combination therapy is showing potential to be a highly effective treatment for SCC.

It’s important to note that these medications are still under clinical trial and not yet widely available or approved for general use. In addition, the best treatment plan for SCC will depend on the patient’s overall health, the stage and location of the cancer, and the patient’s preferences. It’s important to consult with a qualified dermatologist to determine the best treatment options for you.

In conclusion, the latest clinical trial medications for squamous cell carcinoma are showing promising results and have the potential to improve the effectiveness of treatment while minimizing side effects. It is important for patients with SCC to be aware of these new treatment options and to consult with a qualified dermatologist to determine the best treatment plan for them.